[Cannabidiol in cancer treatment].
Study Design
- Tipo di studio
- Review
- Popolazione
- Insomnia patients
- Intervento
- [Cannabidiol in cancer treatment]. None
- Comparatore
- None
- Esito primario
- None
- Direzione dell'effetto
- Mixed
- Rischio di bias
- Unclear
Abstract
BACKGROUND: Cannabis was used for cancer patients as early as about 2500 years ago. Experimental studies demonstrated tumor-inhibiting activities of various cannabinoids more than 40 years ago. In view of the status of tetrahydrocannabinol (THC) as a regulated substance, non-psychotomimetic cannabidiol (CBD) is of particular importance. OBJECTIVES: Efficacy of pure CBD in various animal models as well as initial results (case reports) from patients. METHODS: Review of the literature on animal experiments and observations in humans. RESULTS: Preclinical studies, particularly recent ones, including numerous animal models of tumors, unanimously suggest the therapeutic efficacy of CBD. In isolated combination studies, synergistic effects were generally observed. In addition, CBD may potentially play a role in the palliative care of patients, especially concerning symptoms such as pain, insomnia, anxiety, and depression. Further human studies are warranted.
TL;DR
Preclinical studies, particularly recent ones, including numerous animal models of tumors, unanimously suggest the therapeutic efficacy of CBD, and CBD may potentially play a role in the palliative care of patients, especially concerning symptoms such as pain, insomnia, anxiety, and depression.
Used In Evidence Reviews
Similar Papers
Current psychiatry reports · 2017
Cannabis, Cannabinoids, and Sleep: a Review of the Literature.
Archives of internal medicine · 2007
Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials.
Pharmaceuticals (Basel, Switzerland) · 2012
Cannabidiol in humans-the quest for therapeutic targets.
Nutricion hospitalaria · 2015
NUTRITIONAL AND TOXICOLOGICAL ASPECTS OF SPIRULINA (ARTHROSPIRA).
CNS drugs · 2022
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
The Permanente journal · 2016